Welcome to AiCuris: The Powerhouse for Anti-Infectives

AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

 

 

 

Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

Topical Pritelivir: Phase 2 started

  

 

First subject enrolled in the clinical Phase 2 trial "LipP 1"

"LipP 1", the first clinical Phase 2 trial with topical Pritelivir for treatment of Labial Herpes has started.

Read more ...

NIH Support Preclin. Study AIC649

  

AiCuris Announces U.S. NIH Support of Preclinical Study with AIC649 against Chronic Hepatitis B

AiCuris, a leading company in the discovery and development of drugs against infectious diseases, today announced the start of a preclinical study on the proprietary immune modulator AIC649. 

 Read more ...

Letermovir: positive Phase 3 data

  

AiCuris’ anti HCMV drug Letermovir meets Primary Endpoint

AiCuris’ licensee Merck reports that Letermovir, a prophylactic treatment against HCMV in bone marrow transplant patients, meets Primary Endpoint in Pivotal Phase III Study. 

 Read more ...